N-acetyl cysteine: A new look at its effect on PTZ-induced convulsions

• Published in: Epilepsy research 2023-07, Vol.193, p.107144-107144, Article 107144
• Main Authors: Bilister Egilmez, Cansu, Azak Pazarlar, Burcu, Erdogan, Mumin Alper, Erbas, Oytun
• Format: Article
• Language: English
• Subjects: Acetylcysteine - adverse effects; Animals; Anticonvulsant; Anticonvulsants - adverse effects; Disease Models, Animal; Electroencephalography; Epilepsy; Epilepsy - drug therapy; Myoclonus - drug therapy; N-acetyl cysteine; Oxidative stress; Pentylenetetrazol; Pentylenetetrazole - toxicity; Rats; Rats, Sprague-Dawley; Seizures - chemically induced; Seizures - drug therapy; Superoxide Dismutase
• ISSN: 0920-1211; 1872-6844
• DOI: 10.1016/j.eplepsyres.2023.107144

Epilepsy is widely investigated as a common neurological disease requiring pharmacologically effective agents. N-acetyl cysteine (NAC), has become a remarkable molecule with its role in both antioxidant and glutaminergic modulation. There are many points and processes waiting to be revealed regarding the role of NAC in epilepsy. Pentylenetetrazole (PTZ) was administered to induce seizures in a total number of 48 Sprague-Dawley rats. 35 mg/kg PTZ dose as a sub-convulsive dose was administered to 24 animals to monitor EEG changes, while 70 mg/kg PTZ dose which was a convulsive dose was administered to 24 animals to determine seizure-related behavioral changes with the Racine's scale. 30 min before the seizure-induced procedure, NAC was administered at doses of 300 and 600 mg/kg as pretreatment to investigate anti-seizure and anti-oxidative effects. The spike percentage, the stage of convulsion, and the onset time of the first myoclonic jerk were evaluated to determine the anti-seizure effect. Furthermore, its effect on oxidative stress was determined by measuring both malondialdehyde (MDA) level and superoxide dismutase (SOD) enzyme activity. There was a dose-dependent reduction in the seizure stage and prolonged onset time of the first myoclonic jerk in rats with NAC pretreatment. EEG recordings resulted in a dose-dependent decrease in spike percentages. Moreover, the same dose-dependent changes were observed in oxidative stress biomarkers, both 300 mg/kg NAC and 600 mg/kg decreased MDA levels and ameliorated SOD activity. We can report that 300 mg/kg and 600 mg/kg doses of NAC are promising with their reducing effect on convulsions and have a beneficial effect by preventing oxidative stress. In addition, NAC has been also determined that this effect is dose-dependent. Detailed and comparative studies are needed on the convulsion-reducing effect of NAC in epilepsy. •There is no effective treatment for epilepsy yet.•New agents are needed for the treatment of epilepsy.•The anticonvulsant effect of N-acetyl cysteine is particulary noteworthy.